<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe here a new strategy for the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo>, through the inhibition of NAALADase (N-acetylated-alpha-linked-acidic dipeptidase), an enzyme responsible for the hydrolysis of the neuropeptide NAAG (N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-aspartyl-<z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>) to N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-<z:chebi fb="0" ids="29995">aspartate</z:chebi> and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We demonstrate that the newly described NAALADase inhibitor 2-PMPA (2-(phosphonomethyl)<z:chebi fb="0" ids="17859">pentanedioic acid</z:chebi>) robustly protects against ischemic injury in a neuronal culture model of <z:hpo ids='HP_0001297'>stroke</z:hpo> and in rats after transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Consistent with inhibition of NAALADase, we show that 2-PMPA increases NAAG and attenuates the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced rise in <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Both effects could contribute to neuroprotection </plain></SENT>
<SENT sid="4" pm="."><plain>These data indicate that NAALADase inhibition may have use in <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> in which excessive excitatory amino acid transmission is pathogenic </plain></SENT>
</text></document>